BNP Paribas lowered shares of GlaxoSmithKline plc (LON:GSK) to an underperform rating in a research report sent to investors on Wednesday. The brokerage currently has GBX 1,520 ($20.25) price target on the stock.

A number of other equities research analysts also recently commented on GSK. Shore Capital reissued a buy rating on shares of GlaxoSmithKline plc in a report on Wednesday, June 1st. Beaufort Securities reissued a buy rating on shares of GlaxoSmithKline plc in a report on Friday, June 3rd. Morgan Stanley set a GBX 1,500 ($19.98) target price on GlaxoSmithKline plc and gave the company a neutral rating in a report on Tuesday, May 31st. Citigroup Inc. reissued a buy rating on shares of GlaxoSmithKline plc in a report on Wednesday, July 27th. Finally, JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 1,470 ($19.58) target price on shares of GlaxoSmithKline plc in a report on Wednesday, June 1st. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the company. The company presently has an average rating of Hold and an average price target of GBX 1,676.44 ($22.33).

GlaxoSmithKline plc (LON:GSK) opened at 1641.90 on Wednesday. GlaxoSmithKline plc has a 52-week low of GBX 1,227.50 and a 52-week high of GBX 1,716.50. The firm has a 50-day moving average of GBX 1,658.43 and a 200-day moving average of GBX 1,524.87. The firm’s market cap is GBX 79.81 billion.

The firm also recently announced a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be given a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.12%. The ex-dividend date is Thursday, August 11th.

In other GlaxoSmithKline plc news, insider Cartwright,Stacey bought 461 shares of the business’s stock in a transaction on Friday, July 1st. The shares were bought at an average cost of GBX 1,559 ($20.76) per share, with a total value of £7,186.99 ($9,572.44). Also, insider Witty,Sir Andrew P sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($22.55), for a total value of £169,300 ($225,492.81).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.